Modulation of lnc05 expression

Abstract

Provided herein are methods, compounds, and compositions for reducing expression of lnc05 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a cancer in an individual.

What is claimed is: 
     
         1 . A method comprising administering a lnc05-specific inhibitor to an individual. 
     
     
         2 . The method of  claim 1 , wherein the individual has, or is at risk of having, cancer. 
     
     
         3 . A method of treating, preventing, delaying, or ameliorating cancer in an individual having, or at risk of having, cancer comprising administering a lnc05-specific inhibitor to the individual, thereby preventing, delaying or ameliorating the cancer in the individual. 
     
     
         4 . The method of  claim 3 , wherein the cancer is hepatocellular carcinoma. 
     
     
         5 . The method of  claim 3 , wherein the lnc05-specific inhibitor reduces tumor initiation, tumor progression, cell proliferation, colony formation, or metastasis. 
     
     
         6 . A method of inhibiting expression or activity of lnc05 in a cell comprising contacting the cell with a lnc05 specific inhibitor, thereby inhibiting expression or activity of lnc05 in the cell. 
     
     
         7 . The method of  claim 6 , wherein the cell is a hepatocyte. 
     
     
         8 . The method of  claim 6 , wherein the cell is in an individual. 
     
     
         9 . The method of  claim 8 , wherein the individual has, or is at risk of is hepatocellular carcinoma. 
     
     
         10 . The method of  claim 3 , wherein the individual is human. 
     
     
         11 . The method of  claim 3 , wherein the lnc05 specific inhibitor selected from a nucleic acid, a polypeptide, an antibody, and a small molecule. 
     
     
         12 . The method of  claim 11 , wherein the nucleic acid is a compound comprising a modified oligonucleotide targeting lnc05. 
     
     
         13 . The method of  claim 12 , wherein the compound is single-stranded. 
     
     
         14 . The method of  claim 12 , wherein the compound is double-stranded. 
     
     
         15 . The method of  claim 12 , wherein the modified oligonucleotide is 12 to 30 linked nucleosides in length. 
     
     
         16 . The method of  claim 12 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar moiety, or at least one modified nucleobase. 
     
     
         17 . The method of  claim 16 , wherein the at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage, the at least one modified sugar is a bicyclic sugar or 2′-O-methyoxyethyl, and the at least one modified nucleobase is a 5-methylcytosine. 
     
     
         18 . The method of  claim 16 , wherein at least one modified sugar comprises a 4′-CH(CH 3 )—O-2′ bridge or a 4′-(CH 2 ) n —O-2′ bridge, wherein n is 1 or 2. 
     
     
         19 . The method of  claim 12 , wherein the modified oligonucleotide comprises:
 a gap segment consisting of linked deoxynucleosides;   a 5′ wing segment consisting of linked nucleosides;   a 3′ wing segment consisting linked nucleosides;   
       wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar. 
     
     
         20 . The method of  claim 3 , wherein the lnc05 specific inhibitor is administered parenterally. 
     
     
         21 . The method of  claim 20 , wherein the lnc05 specific inhibitor is administered parenterally by subcutaneous or intravenous administration. 
     
     
         22 . The method of  claim 3 , comprising co-administering the lnc05 specific inhibitor and at least one additional therapy. 
     
     
         23 . The method of  claim 22 , wherein the lnc05 specific inhibitor and the additional therapy are administered concomitantly. 
     
     
         24 . The method of  claim 22 , wherein the lnc05 specific inhibitor and the additional therapy are administered consecutively.